D.E. Shaw & Co
GPCR icon

D.E. Shaw & Co’s Structure Therapeutics GPCR Stock Holding History

D.E. Shaw & Co’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.19M Sell
115,300
-89,490
-44% -$3.96M ﹤0.01% 2232
2026
Q1 		$9.87M Buy
204,790
+196,167
+2,275% +$13.4M 0.01% 1653
2025
Q4 		$600K Sell
8,623
-27,723
-76% -$1.13M ﹤0.01% 3843
2025
Q3 		$1.02M Buy
36,346
+24,181
+199% +$482K ﹤0.01% 3445
2025
Q2 		$252K Buy
12,165
+504
+4% +$11.1K ﹤0.01% 3965
2025
Q1 		$202K Buy
+11,661
New +$286K ﹤0.01% 3931

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

D.E. Shaw & Co's GPCR Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Structure Therapeutics (GPCR) stake by 44% in Q2 2026, selling an estimated $3.96M and leaving 115,300 shares worth $6.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2232.

D.E. Shaw & Co first reported a position in GPCR in Q1 2025 and has held it in 6 quarters since. The position peaked at $9.87M in Q1 2026. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • D.E. Shaw & Co held 115,300 shares of Structure Therapeutics worth $6.19M as of Q2 2026.
  • D.E. Shaw & Co sold 89,490 Structure Therapeutics shares in Q2 2026, an estimated $3.96M.
  • Structure Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2232 holding.
  • D.E. Shaw & Co first reported a position in Structure Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • D.E. Shaw & Co's Structure Therapeutics position peaked at $9.87M in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.